Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115904 | 0.85 | KDM4E (0.50) | CA12CA9KDM4EALPLGAA | |
| SCHEMBL2117668 | 0.84 | KDM4E (0.45) | CA12CA9KDM4EALPLGAA | |
| SCHEMBL29871305 | 0.83 | CA12 (0.57) | CA12CA9KDM4ECA1CA3 | |
| SCHEMBL237720 | 0.83 | CA12 (0.57) | CA12CA9KDM4ECA1CA3 | |
| SCHEMBL30804611 | 0.81 | CA12 (0.55) | CA12CA9KDM4ECA1CA3 | |
| Hydrochloric Acid SCHEMBL31179088 | 0.81 | CA12 (0.55) | CA12CA9KDM4ECA1CA3 | |
| SCHEMBL2118057 | 0.80 | TSHR (0.46) | KDM4EALPLGAAALDH1A1HTT | |
| SCHEMBL10749595 | 0.79 | CA12 (0.53) | CA12CA9KDM4ECA1CA3 | |
| Azetidine SCHEMBL29152261 | 0.75 | CA12 (0.53) | CA12CA9KDM4ECA1CA3 | |
| SCHEMBL9537201 | 0.74 | KDM4E (0.61) | CA12CA9KDM4EALPLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | disclosed |
| EP-2250152-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | FDPS, GGPS1, CTPS1 | CA12 4845/4885CA9 4491/4885KDM4E 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.